Background:In view of ever-increasing end-stage renal disease (ESRD) population but inadequate availability of suitable donors, ABO-incompatible (ABOi) transplantation can be an important void filler. The initial enthusiasm has been slightly lessened in view of higher rate of infections and poor graft survival as compared ABO-compatible transplant. This study was conducted to study the outcomes of ABOi that were performed over the last decade. Methods: Data from 2012 to 2021 was retrospectively analyzed of all the ABOi transplant performed in a tertiary care hospital. The anti-ABO antibody (IgG) titers (1:4) were considered safe before transplantation. Desensitization included Rituximab, Plasma exchange or selective immunoadsorption column. Tacrolimus and mycophenolate mofetil were initiated at day 7. Induction agent included ATG, ATLG, Basiliximab or no induction. Postoperatively, Anti ABO titers were done daily for 2 weeks. Results: A total of 202 patient underwent transplantation, 195 patients whose data for available for 12 months, were included in the study. UTI was the most common source of infection, occurring in almost half (46.1%) of the patients. ABMR (15%) was common in the first year. Death censored patient survival was 86.6% (169/195) at 1 year. Sepsis was the most common of death in more than two-thirds of the population including COVID-19 associated mortality in nine (4.6%) patients. Graft survival was 89.3% (174/195). AMR was the leading cause of graft loss in almost half of the patients. Conclusions: ABOi should be considered in ESRD patients where suitable ABO compatible donor is not available. Higher rate of rejection and, infection are still a major concern.
Background:
COVID-19 is a novel acute infection that is mainly manifested as acute respiratory disease. Information on coronavirus disease-2019 (COVID-19) in CKD patients who are not on dialysis is very limited. We are reporting a single-center observational study on the effect of COVID-19 in CKD patients.
Methods:
A single-center retrospective study with consecutive patients who had eGFR <60 mL/min/1.73 m
2
(CKD-EPI) admitted with COVID-19, from April to July 2020 were included.
Result:
A total of 30 patients were included in the study. Patients of CKD stage 5, 4 and 3 were 50%, 13.3%, and 36.6%, respectively. The mortality rate was 53.3%. Category wise, 9 were in mild; 3 in moderate, and 18 were in the severe COVID category. Twenty-five patients (83.3%) developed acute on CKD. Twenty patients (67%) required renal replacement therapy (RRT). The prognosis of patients who required RRT was poor. High LDH and IL-6 were significantly associated with mortality. Lymphopenia, present in 50% of cases was associated with fatal outcome. There was a 100% survival rate in mild to moderate cases and 11% in severe cases.
Conclusion:
Mortality among hospitalized CKD patients is high.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.